These companies use the creative forces of capitalism to solve big problems—and do well by doing good.

<p>Gilead is a longtime leader in HIV therapeutics and prevention, including antiretroviral treatment and pre-exposure prophylaxis (PrEP) medicines, which are drugs taken to lower the risk of contracting HIV. Gilead has worked with the government of South Africa and the Global Fund to accelerate access to lenacapavir, a long-acting prevention medication that the FDA approved in 2022 to treat drug-resistant HIV. Approximately 7.8 million people in South Africa live with HIV, with an estimated 170,000 new infections each year. 
</p>

Change the World

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

<p>Gilead’s drugs have helped change HIV infection from a death sentence to a manageable condition. In 2012, it launched the first pre-exposure prophylaxis (PrEP) preventive drug for HIV. In June, it won FDA approval for Yeztugo, a PrEP drug requiring only two doses a year—giving it far greater potential efficacy in preventing new infections.
</p>

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The companies on this list are mobilizing the creative tools of capitalism to help solve social problems.

CTW 2023-Gilead

Although the southern United States represent only 33% of the U.S. population, they account for 51% of new HIV diagnoses and 47% of HIV-related deaths in the country. Gilead, which makes a variety of HIV drugs, has launched the Compass Initiative to tackle the factors fueling that disparity. In partnership with more than 390 community organizations across 16 states, Compass’s events and training programs focus on topics including stigma reduction and trauma-informed medical care, with the aim of helping those community groups do more to help combat the spread of HIV. To date, Compass has provided 300,000 people with services, trained 26,000 individuals in leadership development, and provided more than $106 million in grant funding to support outreach to those impacted by HIV.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

The biopharmaceutical company researches and develops antiviral drugs used in the treatment of life-threatening diseases, including HIV and hepatitis. Last October, its intravenous drug remdesivir became the first treatment for COVID-19 approved for emergency use by the FDA.

Fortune Global 500

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-116-Gilead Sciences

This year's Fortune 500 marks the 66th running of the list.

F500-2020-140-Gilead-Sciences

California-based Gilead is a biopharmaceutical firm best known for its hepatitis C cures Sovaldi and Harvoni, though it's been making headlines more recently due to its experimental coronavirus treatment remdesivir.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

World's Most Admired Companies

This year's Fortune 500 marks the 63rd running of the list.

Everybody loves an up-and-comer: 2017's top three-year performers in revenues, profits, and stock returns.

100 Fastest-Growing Companies

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

Here’s our look at 50 companies that do well by doing good.

Too fast to be stopped: 2016's top three-year performers in revenue, profits, and stock returns.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

This year's Fastest-Growing Companies marks the 19th running of the list. In our annual list of public companies with the most stellar three-year profit, revenue, and stock growth, Facebook makes its first appearance.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Company Info

Industry

Location

Industry Rank

Previous Industry Rank

Website

Overall Score

Key Attributes Of Reputation

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Fastest-growing Companies

Headquarters

Sector

Current Streak

Years on List

Revenue, Net Income

Revenue past four quarters ($M)

Net Income past four quarters ($M)

Growth Rates And Ranks

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate

Beat S&P 500 3 Yr Return

Estimated P/E Ratio

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Change The World

Impact Segment

Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes medicines. Gilead’s Veklury (remdesivir) was one of the first antiviral treatments authorized for COVID-19. Gilead also pioneered groundbreaking treatments for HIV that helped transform the fatal virus into a manageable chronic condition. The company continues to expand into oncology and other chronic conditions through acquisitions, such as CymaBay, which developed a treatment for a rare liver disease.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Gilead Sciences (GILD): Company Profile, Stock Price, News, Rankings

legacy

Gilead Sciences

gilead sciences

Thank you for standing by. Today's conference call will be starting in around in a few minutes' time. The call start time is half past.

Good afternoon, everyone, and welcome to Gilead's Second Quarter twenty twenty five Earnings Conference Call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks followed by our Q and A session. Now I'll hand the call over to Jackie Ross, Senior Vice President of Treasury and Investor Relations.

Thank you, Rebecca. Just after market close today, we issued a press release with earnings results for the second quarter of twenty twenty five. The press release, slides and supplementary data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Dea our Chief Commercial Officer, Joanna Mercier our Chief Medical Officer, Dietmar Berger and our Chief Financial Officer, Andrew Dickinson. After that, we'll open the call to Q and A, where the team will be joined by Cindy Paretti, the Executive Vice President of Kite.

Let me remind you that we will be making forward looking statements. Please refer to Slide two regarding the risks and uncertainties relating to forward looking statements that could cause actual results to differ materially. With that, I'll turn the call over to Dan.

Thank you, Jackie, and good afternoon, everyone. The team and I are pleased to be here with you today to share the results of a very successful second quarter. This quarter had special significance, of course, with the FDA approval of lenacapavir or YES-two Go for twice yearly HIV prevention. I want to take this opportunity to thank the many people who contributed to this remarkable achievement. From the Gilead teams who discovered and developed lenacapavir to the participants in the purpose studies as well as the KOLs, advocates, community partners and others who have been part of the lenacapavir journey.

This is truly a milestone moment in the history of HIV with the launch of a groundbreaking innovation that could bend the arc of the epidemic. Moving to the quarterly results, we had another very strong quarter of clinical, commercial and operational execution. Excluding VICLRI, base business sales of $6,900,000,000 grew 4% year over year driven by robust growth across Biktarvy, Descovy, Libdelzi and Trodelvy. Product sales of $7,100,000,000 grew 2% year over year. The strong base business performance was partially offset by lower VICLRII sales due to fewer COVID-nineteen related hospitalizations.

HIV had a very strong second quarter with demand driven growth of 7% year over year more than offsetting the anticipated headwinds from the Medicare Part D redesign. Biktarvy grew 9% year over year to $3,500,000,000 and Descovy grew 35% year over year to $653,000,000 This was Descovy's strongest quarter ever highlighting the growth of the HIV prevention market into which we are now launching YES2Go. It is now seven weeks since FDA approval of YES2Go and we are very pleased with what we're seeing so far. Joanna and Andy will take you through our results in more detail, but overall the strong commercial execution and operating expense discipline year to date support higher expectations for the 2025. As a result, we are increasing our revenue and EPS guidance for the full year.

From a clinical perspective, the second quarter was one of the strongest in Gilead's history. In addition to the FDA approval of Yes2Go, we received positive CHMP opinion from the European Medicines Agency. With more than one million new HIV infections globally each year and over six hundred thousand HIV related deaths, we believe lenacapavir is one of the most important scientific breakthroughs of our time, which brings a sense of urgency and responsibility to reach the communities most in need as quickly as possible. At the same time, we continue to fully evaluate lenacapavir's potential in the clinic. For example, we have just initiated PURPOSE-three 65, a Phase three trial evaluating once yearly lenacapavir for PrEP.

Additionally, we continue to develop seven combination regimens that utilize lanacapavir based molecules for HIV treatment. In the second half of this year, we plan to share updates from ARTISTRY-one and ARTISTRY-two. These Phase three trials are evaluating a potential new single tablet regimen combining bictegravir plus lanacapavir that could further extend the reach of Gilead's current HIV treatment business. Moving to oncology, we announced back to back positive Phase three results for Trodelvy with the top line data from ASCENT-three and the detailed data from ASCENT-four. We now have data that show highly statistically significant and clinically meaningful benefit for Trodelvy across first line metastatic triple negative breast cancer.

Trodelvy is already the leading therapy for second line metastatic TNBC and with these data, we look forward to potentially advancing Trodelvy to the first line setting where it could benefit twice as many patients. In cell therapy, we expect to provide a pivotal update from the Phase II IMGINE-one trial evaluating anitacel for multiple myeloma later this year. Given the compelling efficacy and safety data seen to date, combined with Kite's industry leading manufacturing capabilities, we believe AnitroCell is well positioned as a potential best in class therapy for multiple myeloma. In summary, this is a very special time for Gilead that's underscored with our second quarter results. This highlights the strength of our R and D engine and the level of excellence in our commercial and operational execution.

Having built this positive momentum, we're excited by what's to come with continued innovation that will benefit patients and drive growth across our therapeutic areas. With that, I'll hand over to Joanna.

Thanks, Dan, and good afternoon, everyone. We had another very strong quarter of commercial execution, culminating with the launch of YES TUGO following FDA approval in late June. Second quarter product sales, excluding Veclury of $6,900,000,000 were up 4% year over year, primarily driven by 9% growth in Diktarvy and 35% growth in Descovy. We also delivered encouraging contributions from Libdelvi in its third full quarter of commercial launch and Intradelvi, partially offset by lower HCV sales following a very strong second quarter in 2024. Sequentially, sales in our base business were up 10% driven by growth in HIV, oncology and liver disease.

Including Veclery, total product sales of $7,100,000,000 were up 2% year over year. While Veclery's share of U. S. Hospitalized patients treated for COVID-nineteen remains well over sixty percent, the number of patients impacted by the pandemic continues to decline. This is reflected in second quarter sales of $121,000,000 for Vecluri and also in our updated full year guidance.

Moving to Slide eight, HIV sales of $5,100,000,000 represented very strong 7% year over year growth, primarily driven by increased demand in addition to higher average realized price. Sequentially, sales were up 11% reflecting inventory build and higher average realized price both typical second quarter seasonal dynamics as well as higher demand. On Slide nine, Biktarvy sales of $3,500,000,000 were up 9% year over year with commercial execution supporting a strong increase in demand. Sequentially, sales were up 12% reflecting seasonal inventory build and higher average realized price as well as higher demand. Once again expanded its U.

S. Market share and increased two percentage points year over year to over 51%. Biktarvy continues to lead in share in major markets around the world. Further strengthening Biktarvy's differentiation, FDA recently granted a label expansion to include the treatment of HIV in people with antiretroviral history who are not virologically suppressed with no known or suspected resistance. This new indication addresses an important unmet need for people with HIV, specifically those who come off therapy and then restart treatment.

This label expansion reinforces confidence in Biktarvy to get such individuals to sustained viral suppression. Moving to Descovy, second quarter sales of $653,000,000 increased 35% year over year with growing awareness of PrEP and unrestricted access driving both higher average realized price and higher demand. Sequentially, sales were up 11% reflecting seasonal inventory dynamics and higher demand. Partly driven by strong execution from our commercial team and continued growth ahead of the Yes2Go launch, The U. S.

PrEP market has now expanded to more than 5,000,000 active users. This market continues to grow in the mid teens year over year, highlighting progress on our goal of expanding the HIV prevention market. Additionally, Descovy for PrEP share grew once again this quarter representing more than 40% of The U. S. Market.

Moving to Slide 10, we received FDA approval of Yes2Go as the first twice yearly injection for HIV prevention in mid June and the team has been executing what I consider to be the best planned commercial launch I have seen to date. Revenue in the first days of launch right at the end of the second quarter reflected planned inventory build as we expected. While it's still early days, we're extremely pleased with the feedback from both clinicians and consumers as well as the progress of our early discussions with payers and the effectiveness of our launch preparations and execution to date. Notably, the first YES-two Go prescription was written within hours of approval, with the first product shipped within twenty four hours and the first dose administered within days well ahead of our expectations. Prior to launch or any commercial engagement, YES TUGO's unaided awareness among healthcare providers was at 72% more than twice the typical pre launch awareness with aided awareness at ninety five percent.

I look forward to sharing more about Yes2Go's early performance in the coming quarters. We are well on our way to achieving our target of 75% access for Yes TUGO within six months of launch and ninety percent within twelve months. Outside The U. S, we have just received a positive CHMP opinion and expect a European Commission decision on lenacapavir in the next two months. Our launch preparations in our initial target European territories are underway.

Gilead is committed to facilitating access to lenacapavir for those who could benefit from HIV prevention regardless of where they live. With that in mind, we recently announced a partnership with the global fund to bring lenacapavir to approximately 2,000,000 people in primarily low and lower middle income countries over the next three years. We were also pleased that the World Health Organization and the International AIDS Society both recently announced new HIV prevention guidelines recommending the use of lenacapavir. As we look at the rest of 2025 on slide 11, it's clear that we are seeing very strong performance in both HIV treatment and prevention. With that in mind, we're increasing our full year sales guidance and now expect HIV sales to grow approximately 3% in 2025, up from our prior assumption of flat revenue year over year.

This updated HIV guidance is driven by strong Biktarvy and Descovy performance so far this year and our expectations for the second half. Some additional considerations. First, we've made no change to our assumption regarding the impact of Medicare Part D redesign, which at the start of the year, we expected to impact our HIV business by approximately $900,000,000 in 2025. Excluding this headwind, HIV growth this year would be more than seven percent. Second, given the recency of launch, we have made no changes to launch assumptions surrounding YES-2Go.

And finally, given a broad range of possible policy outcomes, our updated HIV guidance assumes no changes to the current landscape. Moving to liver disease on Slide 12, sales of $795,000,000 were down 4% year over year following a particularly strong 2024. This reflects lower average realized price and lower patient starts in HCV, partially offset by the very strong launch of LIVDELZI as well as demand for HDV and HBV products. For HCV, U. S.

Pricing has been impacted year over year by Medicare Part D redesign, while volume was driven by the timing of purchases in both The U. S. And internationally. In primary biliary cholangitis, we continue to be pleased with LIVDELZ's performance in The U. S.

As well as the early launches in Europe following approval last quarter. Overall, revenue almost doubled from $40,000,000 in the first quarter to $78,000,000 in the second, driven by growing second line PBC market share with our focus on both market expansion and persistence of therapy. Looking ahead, we are particularly encouraged by the demand we're seeing for Libdelzi in new patient starts. That said, and after tremendously strong second quarter, we do expect sequential growth to be more moderate in the third quarter, reflecting continued growth in new patients, but a slower uptake among switch patients where cadence of physician visits remains a gating factor. Moving to Slide 13, Trodelvy sales of $364,000,000 were up 14% year over year and 24% sequentially reflecting Trodelvy's continued strength in metastatic breast cancer and more than offsetting on a year over year basis the expected decline associated with the withdrawal of the bladder cancer indication in The U.

S. Internationally, we have seen strong demand growth both year over year and sequentially, where launch momentum and share gains continue across major markets. Building on our market leadership in second line metastatic triple negative breast cancer, we're working towards filing for approval in the first line setting based on the potentially practice changing results from the ASCENT-three and ASCENT-four trials. As a reminder, there are almost twice as many patients in the first line metastatic setting compared to second line as well as longer duration of therapy and we look forward to expanding the options available for patients in this earlier line setting. For cell therapy on Slide 14 and on behalf of Cindy and the Kite team, second quarter sales of $485,000,000 were down 7% year over year, primarily driven by lower demand, partially offset by higher average realized price.

As expected, our KITE cell therapies continue to face competitive headwinds, although sales were up 5% sequentially, helped by favorable FX impact in addition to higher demand for Yescarta in The U. S. And TACARDAS globally. It's taking time to reduce the barriers to broaden adoption of cell therapy, but we're making progress. For example, FDA recently removed the CAR T class requirement for a REMS program, which we believe will reduce the burden of CAR T administration for healthcare providers, patients and caregivers and we're pleased to see these changes starting to be rolled out across authorized treatment centers.

FDA also made additional changes to the CAR T product labels that will have meaningful impact on patient and caregiver quality of life. This included a 50% reduction in the time patients need to remain near their treating center and a 75% reduction in driving restrictions. We continue to believe that outpatient delivery remains key to broader cell therapy adoption. With that in mind, new real world data shared at ASCO highlighted the viability of outpatient administration for Yescarta. This is also reflected in increasing outpatient adoption over time, suggesting growing physician comfort with the use of Yescarta in this setting.

Our efforts to educate physicians and patients on the potential benefits of a one time CAR T treatment are also ongoing. Most recently, we highlighted new five year overall survival analysis from TACARTIS in B cell acute lymphoblastic leukemia at EHA, the longest follow-up of any CAR T therapy in this indication. Together, these new data support our goals of bringing cell therapy closer to patients and increasing adoption. Wrapping up our second quarter, I want to thank the commercial teams for delivering yet another strong quarter of impact for patients and financial results for Gilead. Any commercial organization is energized by new product launches and we are so fortunate to have several new, exciting and impactful products in our portfolio.

The YES TUGO launch marks a unique moment for Gilead and I know the commercial teams share a sense of both excitement and responsibility given the potential to truly transform the HIV landscape in the coming years. And so with that, I'll hand the call over to Dietmar.

Thank you, Johanna, and good afternoon, everyone. I'd like to start on Slide 16 by recognizing the years of tireless effort across many research and development teams at Gilead, KITE and our partners that contributed to a spectacular quarter of clinical results. In April and May, we announced positive top line results from ASCENT-four and ASCENT-three that showed Trodelvy regimens demonstrated highly statistically significant and clinically meaningful efficacy with the potential to be practice changing in first line metastatic triple negative breast cancer. In May and June, we shared promising early results from our next generation biocistronic CAR Ts in lymphoma and glioblastoma. In June, we shared updated data from our pivotal IMGIGENE-one trial in fourth line and later relapsed and or refractory multiple myeloma that further reinforce our belief in a needle cell's best in class potential.

And also in June, we achieved FDA approval of YES2Go, our breakthrough twice yearly injectable for HIV prevention, which we truly believe has transformative potential. We believe lanacapavir will help bring us closer to our goal of ending the HIV epidemic in the years ahead. You have heard Johanna's excitement about the commercial launch in The U. S. And in July, we were pleased CHMP adopted positive opinions for our EU marketing authorization application and for EU Medicines for All, which enables a streamlined assessment for WHO prequalification and additional global regulatory reviews.

These are critical advances in our plans to help make lenacapavir available to people who need to be protected from HIV globally. This is a moment of pride for this Gilead team and has given me personal pause as I recognize and appreciate the brilliance of the team of scientists that we have here and the determination to keep out innovating ourselves to achieve the best possible experience and outcomes for those we serve. With that in mind, our work in HIV continues. As you can see on Slide 17, with the approval of YES-2Go, we continue to target up to eight additional HIV product launches before the 2033, including five that would come to market by the 2030. In HIV prevention, we have initiated our Phase III trial evaluating once yearly intramuscular injections of lenacapavir for HIV prevention, now called PURPOSE-three sixty five.

If successful, this could launch as early as 2028. In HIV treatment, we continue to expect an update on our new daily oral combination of bictegravir and lenacapavir in the second half of the year from ARTISTRY-one in people with HIV on complex regimens. In addition to ARTIS-three I, we now expect to provide an update for ARTIS-three II, the second Phase III trial for BigLen for virally suppressed people with HIV or people looking to switch regimens. Looking at our weekly HIV treatment programs, we expect a Phase III update on the lenacapavir plus islatravir combination in 2026 with a view to potential launch in 2027. As we announced, our wholly owned weekly WONDERS program evaluating the combination of GS4182, one of our lanacapavir prodrugs and GS1720, one of our long acting integrase inhibitors is on clinical hold pending further analysis.

We're making progress on our other oral long acting candidates and continue to expect our wholly owned once weekly program to be moving forward with a delay of three to six quarters. Among the rest of our leading HIV programs, three are in Phase I, namely our monthly oral and our quarterly and twice yearly injectables. We look forward to sharing updates on these in due course. Finally, we continue to plan for our Phase III study evaluating lenacapavir plus broadly neutralizing antibodies or BNABs as a potential twice yearly injectable treatment. We continue to target commercial launch in 02/1930.

Moving to oncology on Slide 18. Trodelvy's impact in metastatic triple negative breast cancer was reinforced with highly statistically significant and clinically meaningful results in the Phase three ASCENT-three and ASCENT-four studies in the first line setting. At ASCO, we presented potentially practice changing detailed data from ASCENT-four, showing treatment with Trodelvy plus pembrolizumab resulted in an eleven point two month median progression free survival, a thirty five percent improvement versus chemo plus pembro for first line PD L1 positive metastatic triple negative breast cancer. We saw an early trend for improvement in overall survival with Prodalvi plus pembro, though we would note these data are immature. Still, these results are remarkable given the high share of patients who crossed over to Trodelvy following disease progression in the control arm, which would be expected to mask a potential overall survival benefit.

We will be filing for full approval based on the primary median PFS endpoint for both ASCENT-three and ASCENT-four with a potential FDA regulatory decision expected in 2026. We plan to share detailed Phase three ASCEND-three data at an upcoming medical meeting, which will allow it to be considered for future guideline updates. These results are encouraging as we continue to evaluate Rodelvi in earlier lines of breast cancer. In addition to ASCENT-three and ASCENT-four, our other Phase III breast cancer programs include ASCENT-seven in chemo naive hormone receptor positive HER2 negative metastatic breast cancer, evaluating Trodelvy following endocrine and CDK4six inhibitor therapies. This is an event driven trial and we will update you in due course.

And ASCENT-five in high risk early triple negative breast cancer evaluating adjuvant Trodelvy plus pembro. As would be expected with an earlier line trial in a potentially curative setting, it will be several years before we are able to provide an update. We also remain focused on clinical execution of our five other ongoing Phase III programs for Trodelvy and endometrial and upper GI cancers. Moving to Slide 19 and on behalf of Cindy and the Kite team, we were pleased to present new data from across our cell therapy pipeline at the ASCO and EHA congresses. In partnership with Arcellx, data from the IMGINE-one trial at demonstrated the consistent and compelling efficacy and safety profile of edo cel.

We continue to believe edo cel has the potential to offer a best in class profile and we look forward to presenting pivotal data from this trial towards the end of the year. As a reminder, we continue to target 2026 for a commercial launch. From our next generation construct at ASCO, we presented initial data from the biCistronic CD19CD20 KITE-three 63 CAR T, which we believe has shown a promising profile in B cell malignancies, and we have selected KITE-three sixty three to be evaluated in Phase I trials of autoimmune and neuroinflammatory conditions. In the second half of this year, we will decide which program to advance in hematology, choosing between our three next generation CAR T constructs. Additionally, in collaboration with the University of Pennsylvania Perelman School of Medicine, ASCO data on the biocistronic EGFR IL-thirteen RA2 CAR T strengthens proof of concept for expanding CAR Ts to treat solid tumors.

Overall, we remain excited in the potential of our next generation therapies to offer improved efficacy and safety profiles and to reach patients faster as we work towards our goal of bringing potentially curative therapies to patients. Finally, moving to our pipeline milestones on Slide 20. We have had an extremely productive and successful quarter overall. Looking to the rest of the year, we expect the pivotal update from our IMGINE-one trial evaluating enidocel in fourth line or later relapsed or refractory multiple myeloma, the European Commission decision on lanacapavir for PrEP following the recent positive CHMP opinion and a Phase III update for ARTISTRY-one evaluating Biclan in people with HIV on complex regimens. We have also added a new milestone, a Phase III update for ARTISTRY-two, evaluating Biglen in virologically suppressed people with HIV.

Together, ARTISTRY-one and ARTISTRY-two have the potential to support global regulatory filings that could expand the reach of Gilead's HIV treatment business. With that, I'll turn the call over to Andy.

Thank you, Dietmar, and good afternoon, everyone. Starting on Slide 22, our second quarter results show continued strength in execution across the company. Our base business was up 4% year over year to $6,900,000,000 driven by growth in Biktarvy, Descovy, Libdelvi and Trodelvy. Reflecting fewer COVID related hospitalizations, Vecluri sales were down 44% year over year resulting in total product sales of $7,100,000,000 up 2% year over year. Moving to our non GAAP results on slide 23.

Second quarter product gross margin was up 1% from the same quarter last year to 87% driven by a more favorable product mix. R and D expenses were up 9% compared to a relatively low 2024 reflecting investments in clinical manufacturing and study activities. I'll highlight that we continue to expect full year R and D expenses to be roughly flat on a dollar basis from 2024 and year to date R and D expenses are tracking in line with our internal expectations. Acquired IP R and D expenses were $61,000,000 in the second quarter, primarily driven by the Chimera collaboration we announced in June. SG and A expenses were flat year over year with higher sales and marketing expenses primarily related to our HIV franchise offset by lower G and A expenses.

Second quarter operating margin was 46% or 47% excluding acquired IPR and D. The non GAAP effective tax rate was 19% this quarter in line with our expectations. And finally, non GAAP diluted EPS was $2.01 for the quarter. Moving to our full year guidance on slide 24, we had an extremely strong 2025 driven by our HIV portfolio and bolstered by the encouraging momentum in both Libdelvi and Trodelvi. With that in mind, we are updating our full year 2025 guidance as follows.

We now expect product sales excluding Vecluri of approximately $27,300,000,000 to $27,700,000,000 representing an increase of 5,000,000,000 in our base business expectations for 2025. This update reflects HIV growth of approximately three percent year over year driven by the outperformance of Biktarvy and Descovy year to date, FX tailwinds and softer cell therapy expectations where we now expect a modest decline for full year 2025 versus full year 2024. I'll note that our assumptions have not changed in the following areas. Firstly, our assumptions for the impact of Medicare Part D redesign remain unchanged from the beginning of the year and we expect approximately $1,100,000,000 of impact to our business. Secondly, while we're very encouraged by the launch dynamics of YES TUGO to date, we are not updating our assumptions for YES TUGO revenue in the 2025 at this time.

And finally, we have not updated our expectations for the impact tariffs or other changes to the broader policy environment. We continue to expect the impact of known tariffs to be manageable in 2025. Moving to Slide '25, we are reducing our full year 2025 expectations for Vecluri by $400,000,000 to approximately $1,000,000,000 reflecting the current path of the COVID-nineteen pandemic including lower hospitalization rates in the first half and the trends we've seen in the first month of the third quarter. As a result, total product sales is expected to be in the range of 28,300,000,000 to $28,700,000,000 with $05,000,000,000 increase in base business expectations partially offset by lower COVID-nineteen related sales. For other items in the P and L, on a non GAAP basis, we now expect product gross margin to be approximately 86 reflecting strong performance year to date and a more favorable product mix.

We expect R and D expenses to be roughly flat on a dollar basis from 2024, which is consistent with our expectations at the start of the year. And we expect acquired IPR and D to be approximately $400,000,000 reflecting $315,000,000 of expenses so far this year in addition to known commitments and expected milestone payments. SG and A expenses are now expected to decline by a mid to high single digit percentage compared to 2024 updated to reflect higher HIV sales and marketing expenses and other corporate expenses associated with higher 2025 base business expectations. Rounding out the P and L, we expect operating income to be between $13,000,000,000 and $13,400,000,000 our effective tax rate to be approximately 19% consistent with our prior guidance and we expect our full year diluted EPS to be between $7.95 and $8.25 an increase of $0.2 at the midpoint compared to our prior guidance. Looking ahead, we will continue to monitor the macro landscape carefully and we expect that our disciplined approach to operating expense management positions us well to adapt as needed in the months ahead.

On Slide 26, our capital priorities remain unchanged and we returned $1,500,000,000 to shareholders in the second quarter. This included $527,000,000 of share repurchases currently being executed under our 2020 plan. We expect to complete the 2020 program over the next several quarters and our Board recently approved a new $6,000,000,000 program to support continued share repurchases. These repurchases are intended to offset equity dilution at a minimum, but can also be used opportunistically as you've seen in the 2025. Overall, Gilead delivered another very strong quarter of clinical and commercial execution supported by our disciplined operating model.

As we look to the second half of the year, we believe that Gilead is well positioned for near term and long term growth and we remain focused on delivering on our strategic commitments. With that, I'll invite Rebecca to begin the Q and A.

Thank you, Andy. At this time, we'll invite your questions. Please be courteous and limit yourself to one question so we can get to as many analysts as possible during today's Our first question comes from Tyler Van Buren at TD Cowen. Tyler, go ahead. Your line is open.

Great. Hey there. Thanks very much and congratulations on the progress. I know you'll be shocked to hear this question, but can you please elaborate on the early uptake with YES-two Go and whether you expect the early prescriptions to trend linearly from here or if it's still very early in what is expected to be a more of an exponential launch curve?

We are very surprised to get that question.

Tyler, thanks for the question. It's Joanna. Yeah. We're really pleased with the launch so far. And you're right.

It's still early days. We're about six weeks in, but super thrilled to see what's been going on. I think, number one, a lot of that has to do with the readiness of the cross functional teams. As you know, the day that we got or I should say the hour we got the approval, everything was basically ready to turn key and get going. So the the the teams have hit the ground running and, just really proud to see how they're working together in pods across The US to make sure that this happened.

We've already had over about 25,000 customer calls executed in the field and just understanding that our target base is about 15,000. So many of those customers have seen either a representative or a medical sales representative more than once. And that's how we see kind of the uptake and the excitement. When we think about the awareness at launch, it was already kind of double what we usually see in industry at launch, right? You're looking at about a 72% unaided awareness.

Usually, those numbers in the 30s or so. And then, of course, our aided awareness was 95 plus. So we really knew that as we were going into this, we were ready, and now it's up to us to pull it through. You heard me say a couple of early data points around first script within hours, injection within a couple of days and and tracking that super closely. The the piece that maybe is important to to understand as well is how access is playing out here.

We've always said about 70 you should expect 75% or so access at six month time point and then about 90% at twelve percent. And the medical exceptions are basically the way people are working through this. And we have a great field reimbursement team that is there to provide that end to end reimbursement support to make sure we can pull through those scripts as quickly as possible. But different plans will take different times and that's what we're obviously very conscious of. At the same time, I will say we have a couple of early wins that we're really proud of.

One, I would say is the J code, sometimes is having a miscellaneous J code is great, but having the J code come through is actually really important. It just simplifies the whole billing and reimbursement process. And we got confirmation that our J code is coming through for October 1. You probably know from other launches, usually that takes at least two to three quarters. And so that's a little bit ahead of our expectations.

And then we've had some early commercial wins where some plans have come in as of August 1. And then we've had also some state Medicaid wins. And namely, I just want to highlight, we have a couple more than this, but two out of the four biggest prep states, prevention states are, California and Florida, and both of those are on formally as of August 1. So we're really pleased to see that more and more lives are getting access and working through kind of those medical exceptions as we go and really high interest from a lot of our payers to make sure we can have those discussions. So we've engaged with multiple accounts, over 200 accounts we've engaged with to make sure they have all the information they need to make those formulary decisions.

And so that's what we're working through, and that's obviously gonna take a little bit of time as as you know, but I think, we're very well on our way to achieve our goals. So super excited. Hopefully, you can hear it and see all the data to the proof points to support it. I think we have the right team, the right attitude, and the responsibility to make sure we really make a difference here with Yes2 though and bend the curve of this epidemic. So stay tuned as a little bit more data comes through in the next quarter and more to come.

Thanks, Joanna. Thanks, Tyler for the question. I just want to add, I'm really impressed with the team's early launch support here and we look forward to updating you in quarters to come. Can we have the next question please?

Our next question comes from Terence Flynn at Morgan Stanley. Go ahead Terence. Your line is open.

Great. Thanks so much for taking the question and congrats on all the progress as well. Joanna, you mentioned Descovy had one of its best quarters ever. I think if you look at the growth trajectory there, it's obviously been very robust and looks to be tracking well above the 8% rate that I think is implied in your longer term guidance for the prep market when you guys look out to 02/1930. So just wondering how durable this kind of a growth rate is given what you're seeing out there in the market and a lot of the work you're doing that you've done ahead of the YES2Go launch.

And then just one clarification, can you just comment on the accuracy of YES2Go IQVIA data for us if you have any visibility there? Thank you.

Sure. Thanks, Terence. So a couple of things. One is the Prep market is growing nicely at about double digit, right, about 15% or so year on year. And that obviously has to do with a lot of the work that we've been pulling through, a lot of initiatives in the field to increase awareness about prevention and the importance of prevention.

And that's why we were excited to share that those numbers are growing quite actively, and we're at about 500,000 or so active users in PrEP, which is well on our way to kind of those goals that you were referring to of over 1,000,000 by mid-30s. We do think that there's an opportunity for us to basically continue that growth in the marketplace, especially with the excitement with Yes2Go. I think the purpose one and purpose two data are just so powerful that they're really having impact in the field. So we will continue to drive that. To your comments around Descovy and the incredible performance that we've been seeing with Descovy and right that 35% share, a lot of that has to do with basically continued favorable access that we've seen over the last six to nine months or so, where we're seeing the co pays come down to $0 in many cases, our access basically jumped up a little bit.

And we're now at about if you think about unrestricted access, we're at about 88% of total lives covered. We are about 98% total covered lives. So about 10% still have a little bit of restriction, either step edit or prior op, but that's actually a big jump. And then the teams have done an incredible job with those plans that had those changes is really to increase those shares of Descovy in those plans. So that's what you're seeing in the uptake.

What I would suggest, though, is as Yes2Go gets traction and ramps up over the next coming quarters, you will probably see a little bit of a decline because the intent with Yes2Go is obviously to look at the total PrEP market and make sure that we're differentiating there across all the orals as well as other long acting. So you will see a little bit of a shift in the mix, right, as we go forward. Hopefully, addressed that question. And your quick comment on IQVIA data, listen, it's still really early, but we do believe IQVIA data is directionally aligned. It's just some accounts, some channels are not represented in IQVIA, as you well know, so they're not reflected in the data.

I think we're going to need a couple of more quarters to stabilize as you've seen in the past with other launches. Having said that, we're so pleased kind of with what we're seeing in the initial uptake, the customer response. I think I will tell you the excitement is palpable internally, externally. And I would also say that we're also tracking really closely kind of the the customer uptake as well. Right?

So as it goes through into the reimbursement because our teams are making sure that we can pull those scripts through, and what really matters through IQVIA is users that are getting the injection. So we're tracking both of those really closely. So stay tuned. But I think a couple more quarters will help us kind of normalize that data.

As a reminder, we ask that you please limit yourself to one question so we can get to as many analysts as possible on today's call. Our next question comes from Umer Raffat at Evercore. Umer, go ahead. Your line is open.

Hi, guys. Thanks for taking my question and congrats on all the progress with Yatugu. I figured I'll go in a different direction on potentially a risk factor for the business. In a scenario where the industry does converge around an MFN proposal, which is focused on Medicaid, How do you see the impact to Gilead business from a revenue perspective? And obviously inclusive of the mandatory and CPI rebates, you do pay to Medicaid already. Thank you very much.

Yeah. Thanks, Umer. Maybe I'll start and then I'll hand it over to Joanna to talk specifically about the Medicaid portion of it. I just want to be clear that obviously we are having discussions and working with the administration on the whole topic of MFN. I would say just as a backdrop to all this that given the general business uncertainty in the country and also some of the sector specific uncertainty, It's even more important that we're at this stage in Gilead's history of driving forward with all these new launches controlling operating expenses.

And I remind you as you know we have very limited patent exposure until the 2033 with a very strong clinical development plan to be able to support the patients with that medicine prior to 02/1933. So I'll just put that in the backdrop. Obviously, we very much support the concept of finding ways to have patients better afford their medicine in this country while also preserving the right ecosystem here. Now specifically related to your Medicaid question, I'll hand it over to Joanna to talk about how that could or could not impact us.

Right. I mean, so you know Medicaid business for us and HIV, I'm going to focus on HIV, biggest piece of our business is around mid to lower 20s. And so that is something that is important to us. Remember, the co pays, so the patient out of pocket cost for Medicaid is incredibly low. It's either zero dollars or a couple of dollars per script.

And there's a lot of support for that. I mean, obviously, what we're tracking is also not just potential demo projects and things like that with MSM, but we're also tracking the current legislation with Medicaid as to the big beautiful bill. And we are tracking that realizing that most of those have implications late twenty twenty six into 2027, so no immediate impact at this point in time. Having said that, all of that said, HIV is very different. And it is a disease that obviously if you don't treat it, I think the repercussions and the consequences are not just that individual patient, they could be much broader, such as a local epidemic of HIV in The United States.

And so that's why many individuals or most individuals that are diagnosed with HIV, there's really always a safety net program to support them in their treatment. And whether that's state programs, ADAP programs, foundations, or even Gilead's patient access programs, these are all pieces of the puzzle that we're thinking through to make sure we wrap around to make sure that those patients get coverage and access to the medicines they need.

Our next question comes from Evan Finkerman at BMO Capital Markets. Evan, go ahead. Your line is open.

Thank you for the question and really congrats on the progress. Given the importance of the Eptuga launch and the recent changes to the HHS Preventative Task force. If PrEP is removed as a preventative medicine broadly, how does this change your approach to commercialization? Is there a potential also impact to the COVID? Thank you so much.

I heard most of that. It's Joanna, Evan. I'll take that one. Yes. So listen, let me start by saying the USPSTF guidance is something we truly support.

We believe in preventative services. We think it's very important across all diseases, but namely in HIV when you think about prevention. The current guidelines are well enforced. They support the $0 copay. And without access restrictions or step edits or whatnot for HIV prevention.

And we believe that also includes Yes2Go as we're going forward with those conversations with the plan. As I mentioned earlier, Descovy is well covered, 88% of access with no restrictions. Having said all of that, if there was to be a change in the future, not that we foresee that, if there was to be changed, I just want to remind you that these guidelines didn't really have legs until probably less than a year ago, probably about two, three quarters ago. And before that, the prevention market was still growing very strong, same rates basically that we're seeing today. And we were very successful with Descovy at about a 40% share or so.

We're now closer to about a little bit towards the 44%, 45% share now, and the market is still growing at around the same rate. So we do believe that whether we have USPSTF, that's ideal. If it was to change in any way, we still believe we could work through it and just work closer with our payers to make sure that people have access to HIV prevention moving forward just as they do today.

Our next question comes from Chris Schott at JPMorgan. Chris, go ahead. Your line is open.

Great. Thanks so much and congrats on the progress. I just wanted to ask about the treatment pipeline and specifically just elaborate on your confidence on the 04/1720, the weekly treatment combo, the WONDERS program following the clinical hold announced earlier this year. I guess just kind of next updates we should be watching for on that combo? And just how does that stack up relative to some of the other treatment combos that you're working on? Thank you.

Hi, Chris. We'll get Pete Marsworth here. Yes. Chris, for the question. Our confidence in the treatment pipeline is high, right?

And remember, we not only work on weekly approach, we also work on daily, monthly, every three months and every six months approach. So the pipeline is deep. We have a variety of different molecules. And if you look at four thousand one hundred eighty two and seventeen twenty, one of them is a lenacapavir prodrug, the other one is an INSD and we have several other molecules of those classes in our portfolio. So what we're currently doing is we're trying to understand the data further.

We're doing preclinical and clinical analysis to really isolate the observations that we had to make sure we understand which of the molecules led to that observation. And then to move forward expeditiously with one of our other molecules that we have in the portfolio in a new combination to really get that weekly treatment opportunity to patients. I also want to mention that we obviously have our Phase three island program, isletrovir and lanacapavir ongoing, which is currently in Phase three. The next update on that program is coming 2026 and the estimated launch for that one is in 2027. With regards to our wholly owned program, kind of the Wonders program and the succession of that, we will update you in due course.

Our next question comes from Geoff Meacham at Citibank. Geoff, go ahead. Your line is open.

All right. Great. Hey, guys. Thanks for the question. You had another one on YES TUGO.

It seems like the OUS contribution, I think it's going be much bigger when you compare to Descovy or Truvada and PrEP. JoAnna, I'm not asking for guidance, but when you think about The U. S. Versus OUS contribution for HIV treatment, could that ultimately mirror what you will see in PrEP kind of at the peak? I guess that's what I'm asking is that the outside of The U.

S. Market is one that's sort of novel and new for you guys and want to get some context there. Thanks.

Thanks, Jeff. I do think that you're right. I think there's a broader opportunity with Yes2Go ex U. S. And a lot of that has to do, right, with Descovy, we were kind of challenged in many markets to compare it with Truvada.

And Truvada was generic in many of those markets. With Yes2Go, I think with the innovation, the transformational value that we are bringing for markets that truly recognize the need for something else in HIV prevention and recognize the value of lanacapavir and what it brings to their populations or their specific target populations where you see an HIV incidence that is very high. I really do think there's an opportunity for us, to have broader footprint than just where we are today with Descovy, for example. And so I think at you know, to your point at stable at steady state or at peak, I do think maybe that'll take a little bit of time because I think the challenge from a reimbursement standpoint will not be, simple. But I do think for the countries that have literally said, and been very outspoken that they wanna bend the curve or that they're not meeting their 2,030 targets, which nobody is, this is really an opportunity for us to partner with those stakeholders and make sure that Yes2Go is available for those countries.

Our next question comes from Mohit Bansal at Wells Fargo. Mohit, go ahead. Your line is open.

Great. Thank you very much. And Joanna, you are very popular today, so one more for you. So so the question is regarding the logistics as well as the the safety side of it. So just wanted to understand for you guys to go the logistics dynamic because this is a pay this is a prescriber base that is used to orals and now they're going to use an injection which is also a doctor's offices.

Gilead Sciences (GILD) Q2 2025 Earnings Call Transcript

Company Participants